Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

January 27, 2017

Study Completion Date

July 28, 2021

Conditions
Multiple Myeloma
Interventions
DRUG

Pomalidomide and Dexamethasone

Trial Locations (22)

1090

Medizinische Universitat Wien, Vienna

1160

Wilhelminenspital der Stadt Wien, Vienna

4020

Krankenhaus der Elisabethinen Linz, I Interne Abteilung, Linz

11528

Alexandra Hospital, University of Athens, Athens

20122

Ospedale Maggiore Policlinico Mangiagalli Regina Elena, Milan

23900

S.C. Oncologia Medica, Lecco

28006

Hospital de La Princesa, Madrid

37007

CEIC Hospital Universitario de Salamanca, Salamanca

42100

Arcispedale Santa Maria Nuova, Reggio Emilia

46017

Hospital Universitario Doctor Peset, Valencia

60126

Azienda Ospedaliero Universitaria Ospedali, Ancona

69120

Medizinische Klinik und Poliklinik V Hamatologie, Onkologie und Rheumatologie, Neuenheimer Feld 410

72076

University Hospital Tubingen, Tübingen

75475

Hopital Saint Louis, Paris

86021

CHU de Poitiers, Poitiers

87042

Hopital Dypuytren-CHU de Limoges, Limoges

1081 HV

VU University Medical Center VU Medisch Centrum, Amsterdam

3075 EA

Daniel den Hoed Kliniek Medical Oncology, Erasmus MC, Rotterdam

B15 2TH

Queen Elizabeth Hospital UHB NHS Foundation Trust, Birmingham

DD1 9SY

Ninewells Hospital and Medical School, Dundee

OX37LJ

Oxford Radcliffe Hospital ICRF Medical Oncology Unit, Headington

SE1 9RT

St Thomas' HospitalGuy's Hospital Dept. of Haematology, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY